Abstract:A functional pharmacokinetic/pharmacodynamic (PK/PD) index that could simultaneously describe three controlling PD variables, i.e., bactericidal activity, postantibiotic effect (PAE), and susceptibility, in relation to pharmacokinetics, was designed using an in vitro kinetic model. Tobramycin was tested against one standard and five clinical strains of Pseudomonas aeruginosa. The organisms showed minimum inhibitory concentrations (MICs) ranging between 1 and >1000 microg/ml. The model allowed antibiotic concen… Show more
“…26 However, as a pharmacodynamic parameter, potency does not account for patient pharmacokinetics such as C max and AUC. [7][8][9][10][11][12][13][14][15] Potency rankings did not accurately reflect predicted efficacy rankings.…”
Section: Discussionmentioning
confidence: 99%
“…Within the last 10 years, emphasis has been placed on the importance of combining pharmacodynamic and pharmacokinetic data as a basis for predicting potential antimicrobial efficacy in a patient. [7][8][9][10][11][12][13][14][15] Among predictors most commonly associated with fluoroquinolone efficacy are the ratio of C max to MIC (C max /MIC, sometimes referred to as an inhibitory quotient or IQ), and the ratio of area under the plasma drug concentration versus time curve to the MIC (AUC/MIC; sometimes referred to as area under the inhibitory curve or AUIC). [7][8][9][10][11][12][13][14][15] In vitro studies for concentration-dependent antimicrobials (including fluoroquinolones) suggest that antibacterial efficacy is more likely if the C max /MIC is $ 10, 8,9 or the AUC/MIC is $125, particularly for Gram-negative organisms.…”
E. coli resistance to fluoroquinolones approximated 40%. For susceptible isolates, enrofloxacin, marbofloxacin, and ciprofloxacin more consistently reached indices associated with predicted efficacy, but only at the high dose.
“…26 However, as a pharmacodynamic parameter, potency does not account for patient pharmacokinetics such as C max and AUC. [7][8][9][10][11][12][13][14][15] Potency rankings did not accurately reflect predicted efficacy rankings.…”
Section: Discussionmentioning
confidence: 99%
“…Within the last 10 years, emphasis has been placed on the importance of combining pharmacodynamic and pharmacokinetic data as a basis for predicting potential antimicrobial efficacy in a patient. [7][8][9][10][11][12][13][14][15] Among predictors most commonly associated with fluoroquinolone efficacy are the ratio of C max to MIC (C max /MIC, sometimes referred to as an inhibitory quotient or IQ), and the ratio of area under the plasma drug concentration versus time curve to the MIC (AUC/MIC; sometimes referred to as area under the inhibitory curve or AUIC). [7][8][9][10][11][12][13][14][15] In vitro studies for concentration-dependent antimicrobials (including fluoroquinolones) suggest that antibacterial efficacy is more likely if the C max /MIC is $ 10, 8,9 or the AUC/MIC is $125, particularly for Gram-negative organisms.…”
E. coli resistance to fluoroquinolones approximated 40%. For susceptible isolates, enrofloxacin, marbofloxacin, and ciprofloxacin more consistently reached indices associated with predicted efficacy, but only at the high dose.
“…These drugs are best represented by the fluoroquinolones and aminoglycosides (both of which result in irreversible inhibition of their targets). 31,32 More recently, the effectiveness of concentration-dependent drugs has been best predicted by the area under the inhibitory curve (AUIC), the ratio of the AUC (area under the curve for 24 hours, which is influenced by both dose and interval) to the MIC. Their effectiveness is predicted by comparing the C max with the MIC of the infecting organism.…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.